Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
Tufts Medical Center
Not signed up.
Complex, 3D Skin-like Tissues for Preclinical Testing of Diabetic Ulcer Therapy
We seek to develop more complex and predictive, in vitro, human 3D tissue wound healing models for preclinical drug screening that will effectively test the safety and efficacy of novel therapeutics for Diabetic foot ulcers (DFU). This will help meet the urgent need to develop next generation treatments for these and other complications of diabetes by providing more cost-effective ways of predicting the success or failure of drugs designed to treat DFUs before they enter human clinical trials. To fill this critical need, our immediate goal is to characterize and test diabetes-specific, preclinical wound healing models fabricated as in vitro, 3D tissues. We will develop a novel DFU wound repair platform that will have 3 important, new features: 1- harbor DFU fibroblasts and macrophages from a spectrum of Type II DFU patients, 2- a higher throughput format (24 well) than existing tissues and 3- will eliminate all animal products and incorporate only human cells and tissues. This will improve upon our existing DFU wound healing models by creating more complex tissues that will be an important advance over currently available monolayer, tissue cultures. We expect to learn that novel DFU patient-specific, 3D tissue wound models that mimic chronic wounds like DFU can be optimized as a critical step towards developing high-impact, high-throughput human preclinical drug testing platforms for DFU through two SPECIFIC AIMS: 1- To optimize human, DFU patient-specific 3D tissue models harboring primary DFU-derived fibroblasts and macrophages and 2- To test, characterize and optimize these 3D tissue models of DFU wound re-epithelialization. Our research is based on our previous work showing that: 1- DFU patient-derived fibroblasts generate 3D tissue models that simulate defective wound healing of DFUs in vivo, 2- primary, DFU-derived macrophages retain their M1/M2 polarization states when incorporated into 3D tissue models and 3- 3D skin-like tissues can be fabricated with fibroblasts, macrophages and extracellular matrix in a 24-well, tissue format. The success of our strategy will significantly improve our ability to identify biomarkers of DFU and efficiently screen candidate drug for DFU treatment at an early stage in their development in a reproducible and convenient tissue model. By successfully developing small-format, 3D tissues, we will lay the groundwork to incorporate these tissues into “tissues on chips” formats. This will shift preclinical drug screening for DFU towards the dissemination, scale-up and commercialization of preclinical wound healing models that will prioritize and streamline drug discovery for DFUs so they can safely be used in human clinical trials.
Drag a column header and drop it here to group by that column
Complex, 3D Skin-like Tissues for Preclinical Testing of Diabetic Ulcer Therapy (Garlick, Jonathan)
View Progress Report Document
No uploaded documents found.
Year: 2021; Items: 1
A Novel Three-Dimensional Skin Disease Model to Assess Macrophage Function in Diabetes.
Smith A, Watkins T, Theocharidis G, Lang I, Leschinsky M, Maione A, Kashpur O, Raimondo T, Rahmani S, Baskin J, Mooney D, Veves A, Garlick J
Tissue engineering. Part C, Methods
, 2021 (27), 49 - 58
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Wound Healing Committee has the principal function of furthering the mission of the consortium with regard to diabetic wound healing.
Curation Flag Information
New comment to be added:
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!